| Autor: |
Tejedor M; Department of Oncology, Hospital de Navarra, Pamplona, Spain. jj.valerdi.alvarez@cf.navarra.es, Valerdi JJ, Arias F, Dominguez MA, Pruja E, Mendez L, Illarramendi JJ |
| Jazyk: |
angličtina |
| Zdroj: |
Cytokines, cellular & molecular therapy [Cytokines Cell Mol Ther] 2000 Mar; Vol. 6 (1), pp. 35-9. |
| DOI: |
10.1080/13684730050515895 |
| Abstrakt: |
An open-label, non-randomized study evaluated the feasibility and efficacy of filgrastim (recombinant methionyl human granulocyte colony-stimulating factor, r-metHuG-CSF) to prevent mucositis induced by accelerated hyperfractionated radiotherapy (1.6 Gy b.i.d., total dose 67.2 Gy in six weeks with a two-week split) and concomitant chemotherapy (cisplatin, 20 mg/m2/day, days 1-5 by continuous intravenous infusion) in patients with laryngeal carcinoma. Filgrastim 300 microg/day was administered on days 1, 3, and 5 in weeks 2-6 of radiotherapy, after the second fraction. Twenty patients (three stage II, six stage III, and eleven stage IV, according to AJCC) were enrolled in the trial. Oral mucosal toxicity was grade 2 in nine patients (45%), grade 3 in eight (40%), and grade 4 in three (15%). Severe hematological toxicity (WHO criteria) was uncommon. Nineteen patients (95%) completed the treatment in the planned time. Overall survival was 55% at three years. The administration of filgrastim with this regimen was feasible, and it appeared to reduce the severity and duration of mucositis induced by the combined treatment. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
